|
Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series |
Jan 2021 |
Annals of Hematology |
Aplastic Anemia |
|
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry |
May 2020 |
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes |
Nov 2019 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Clinical decision-making and treatment of myelodysplastic syndromes |
Dec 2023 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
Jun 2023 |
American Journal of Hematology |
Aplastic Anemia |
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
Apr 2023 |
American Journal of Hematology |
Aplastic Anemia |
|
Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management |
Aug 2020 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" |
Jan 2021 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
|
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes |
Jan 2021 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough |
Jun 2023 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
